These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 31909823)

  • 41. Methylated Septin 9 and Carcinoembryonic Antigen for Serological Diagnosis and Monitoring of Patients with Colorectal Cancer After Surgery.
    Ma ZY; Law WL; Ng EKO; Chan CSY; Lau KS; Cheng YY; Shin VY; Kwong A; Leung WK
    Sci Rep; 2019 Jul; 9(1):10326. PubMed ID: 31316143
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Value of carcinoembryonic antigen and cytokeratins for the detection of recurrent disease following curative resection of colorectal cancer.
    Fernandes LC; Kim SB; Saad SS; Matos D
    World J Gastroenterol; 2006 Jun; 12(24):3891-4. PubMed ID: 16804977
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Personalized circulating tumor DNA monitoring improves recurrence surveillance and management after curative resection of colorectal liver metastases: a prospective cohort study.
    Li Y; Xu J; Hu X; Chen Y; Liu F; Chen Y; Ma X; Dong Q; Sun L; Mo S; Zhang L; He X; Tong S; Wu H; Li W; Cai S; Zhu S; Pan Q; Peng J
    Int J Surg; 2024 May; 110(5):2776-2787. PubMed ID: 38445460
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery and validation of methylation signatures in blood-based circulating tumor cell-free DNA in early detection of colorectal carcinoma: a case-control study.
    Sui J; Wu X; Wang C; Wang G; Li C; Zhao J; Zhang Y; Xiang J; Xu Y; Nian W; Cao F; Yu G; Lou Z; Hao L; Liu L; Li B; Zhang Z; Cai S; Liu H; Lan P; Zhang W
    Clin Epigenetics; 2021 Feb; 13(1):26. PubMed ID: 33536049
    [TBL] [Abstract][Full Text] [Related]  

  • 45. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow-up? A systematic review and secondary analysis of a randomised controlled trial.
    Shinkins B; Nicholson BD; James T; Pathiraja I; Pugh S; Perera R; Primrose J; Mant D
    Health Technol Assess; 2017 Apr; 21(22):1-60. PubMed ID: 28617240
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial.
    Shinkins B; Primrose JN; Pugh SA; Nicholson BD; Perera R; James T; Mant D
    Br J Surg; 2018 May; 105(6):658-662. PubMed ID: 29579327
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recurrence risk assessment for stage III colorectal cancer based on five methylation biomarkers in plasma cell-free DNA.
    Wang W; Zhu X; Zhang X; Lei C; Zeng Z; Lan X; Cui W; Wang F; Xu S; Zhou J; Wu X; Deng H; Li X; Fan J; Ding Y; Huang Z; Liang L
    J Pathol; 2023 Apr; 259(4):376-387. PubMed ID: 36573552
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Circulating tumour DNA-Based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis.
    Zheng J; Qin C; Wang Q; Tian D; Chen Z
    EBioMedicine; 2024 May; 103():105109. PubMed ID: 38614009
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer.
    Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C
    Tumour Biol; 2004; 25(5-6):228-34. PubMed ID: 15627885
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Circulating tumor DNA is a sensitive marker for routine monitoring of treatment response in advanced colorectal cancer.
    Zou D; Day R; Cocadiz JA; Parackal S; Mitchell W; Black MA; Lawrence B; Fitzgerald S; Print C; Jackson C; Guilford P
    Carcinogenesis; 2020 Nov; 41(11):1507-1517. PubMed ID: 32955091
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences.
    Henriksen TV; Tarazona N; Frydendahl A; Reinert T; Gimeno-Valiente F; Carbonell-Asins JA; Sharma S; Renner D; Hafez D; Roda D; Huerta M; Roselló S; Madsen AH; Løve US; Andersen PV; Thorlacius-Ussing O; Iversen LH; Gotschalck KA; Sethi H; Aleshin A; Cervantes A; Andersen CL
    Clin Cancer Res; 2022 Feb; 28(3):507-517. PubMed ID: 34625408
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum.
    Bhatavdekar JM; Patel DD; Giri DD; Karelia NH; Vora HH; Ghosh N; Shah NG; Trivedi SN; Balar DB
    Br J Cancer; 1992 Nov; 66(5):977-80. PubMed ID: 1419646
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diagnostic value of carcinoembryonic antigen and carcinoma antigen 19-9 for colorectal carcinoma.
    Zhang SY; Lin M; Zhang HB
    Int J Clin Exp Pathol; 2015; 8(8):9404-9. PubMed ID: 26464695
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development and validation of postoperative circulating tumor DNA combined with clinicopathological risk factors for recurrence prediction in patients with stage I-III colorectal cancer.
    Gao Z; Huang D; Chen H; Yang Y; An K; Ding C; Yuan Z; Zhai Z; Niu P; Gao Q; Cai J; Zeng Q; Wang Y; Hong Y; Rong W; Huang W; Lei F; Wang X; Chen S; Zhao X; Bai Y; Gu J
    J Transl Med; 2023 Jan; 21(1):63. PubMed ID: 36717891
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of carcinoembryonic antigen for the detection of recurrent disease following curative resection of large-bowel cancer.
    Wichmann MW; Müller C; Lau-Werner U; Strauss T; Lang RA; Hornung HM; Stieber P; Schildberg FW
    Langenbecks Arch Surg; 2000 Jul; 385(4):271-5. PubMed ID: 10958511
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The diagnostic accuracy of carcinoembryonic antigen to detect colorectal cancer recurrence - A systematic review.
    Sørensen CG; Karlsson WK; Pommergaard HC; Burcharth J; Rosenberg J
    Int J Surg; 2016 Jan; 25():134-44. PubMed ID: 26700203
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluating the Role of Methylated Circulating Tumor DNA in Combination With Pathological Prognostic Factors for Predicting Recurrence of Colorectal Cancer.
    Al Naji H; Winter JM; Pedersen SK; Roy A; Byrne SE; Young GP; Symonds EL
    Biomark Insights; 2024; 19():11772719241232870. PubMed ID: 38426070
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Carcinoembryonic antigen testing after curative liver resection for synchronous liver metastasis of colorectal cancer: a Japanese multicenter analysis.
    Okazaki S; Baba H; Iwata N; Yamauchi S; Sugihara K
    Surg Today; 2017 Oct; 47(10):1223-1229. PubMed ID: 28439715
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data.
    Huang K; Qu H; Zhang X; Huang T; Sun X; He W; Li M; Lin L; Xu M; Chen S; Xia L
    Cancer Biomark; 2019; 26(3):313-322. PubMed ID: 31561327
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer.
    Takagawa R; Fujii S; Ohta M; Nagano Y; Kunisaki C; Yamagishi S; Osada S; Ichikawa Y; Shimada H
    Ann Surg Oncol; 2008 Dec; 15(12):3433-9. PubMed ID: 18846401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.